Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$3.27M (7 inflow days, 13 outflow days).
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 31.4% of shares outstanding.
Reported short interest has fallen from 22.38% to 20.42% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +152,628 | 0.2% |
| BlackRock | Mutual Fund | 2026/Q3 | +978,389 | 8.5% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +908,099 | 5.3% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +871,826 | 4.5% |
| Eversept Partners, L.P. | Hedge Fund | 2026/Q3 | +747,994 | 0.9% |
| Bank of America Corporation | Public Company | 2026/Q3 | +520,794 | 0.9% |
| Wellington Management Group | Mutual Fund | 2026/Q3 | +413,115 | 3.2% |
| Perceptive Advisors LLC | VC/PE Fund | 2026/Q3 | +375,000 | 3.2% |
| Braidwell LP | Hedge Fund | 2026/Q3 | +373,500 | 2.5% |
| Trexquant Investment LP | Hedge Fund | 2026/Q3 | +296,347 | 0.4% |
| Two Sigma Investments, LP | Hedge Fund | 2026/Q3 | +245,339 | 0.9% |
| Hood River Capital Management LLC | Mutual Fund | 2026/Q3 | +236,696 | 1.9% |
| Catalio Capital Management, LP | VC/PE Fund | 2026/Q3 | +188,955 | 1.3% |
| Millennium Management LLC | Hedge Fund | 2026/Q3 | +181,623 | 1.2% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +175,255 | 0.6% |
Institutional buy/sell activity by reporting period, largest moves first.
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 10 Jun 2026 | Richard van den Broek | Director | Other Derivative Acquisition | +15,000 | $11.60 | 15,000 |
| 10 Jun 2026 | Linda Grais | Independent Director | Other Derivative Acquisition | +15,000 | $11.60 | 15,000 |
| 10 Jun 2026 | Ian T. Clark | Independent Director | Other Derivative Acquisition | +15,000 | $11.60 | 15,000 |
| 10 Jun 2026 | Peter Thompson | Co-Founder & Independent Director | Other Derivative Acquisition | +15,000 | $11.60 | 15,000 |
| 10 Jun 2026 | David Moore | Director | Open Market Acquisition | +21,700 | $11.53 | 21,700 |
| 10 Jun 2026 | David Moore | Director | Other Derivative Acquisition | +15,000 | $11.60 | 15,000 |
| 17 May 2026 | Richard Miller | Co-Founder, President, CEO & Chairman of the Board | Open Market Acquisition | +6,932 | $12.05 | 2,331,742 |
| 27 Jan 2026 | Peter Thompson | Co-Founder & Independent Director | Derivative Exercise and Retained | +210,000 | $15.00 | 210,000 |
| 3 Dec 2025 | Richard Miller | Co-Founder, President, CEO & Chairman of the Board | Other Derivative Acquisition | +1,000,000 | $8.81 | 1,000,000 |
| 3 Dec 2025 | Leiv Lea | Chief Financial Officer | Other Derivative Acquisition | +400,000 | $8.81 | 400,000 |
| 3 Dec 2025 | Jeffrey Arcara | Chief Business Officer | Other Derivative Acquisition | +100,000 | $8.81 | 100,000 |
| 3 Dec 2025 | William Jones | Senior Vice President of Pharmaceutical Development | Other Derivative Acquisition | +400,000 | $8.81 | 400,000 |
| 1 Oct 2025 | David Moore | Director | Other Derivative Acquisition | +30,000 | $7.04 | 30,000 |
| 26 Jun 2025 | OrbiMed Advisors LLC | Derivative Exercise and Sale | -1,176,332 | $4.16 | 7,165,006 | |
| 26 Jun 2025 | OrbiMed Advisors LLC | Derivative Exercise and Retained | +221,352 | $3.50 | 7,165,006 | |
| 11 Jun 2025 | Linda Grais | Independent Director | Other Derivative Acquisition | +15,000 | $4.24 | 15,000 |
| 11 Jun 2025 | Ian T. Clark | Independent Director | Other Derivative Acquisition | +15,000 | $4.24 | 15,000 |
| 11 Jun 2025 | Peter Thompson | Co-Founder & Independent Director | Other Derivative Acquisition | +15,000 | $4.24 | 15,000 |
| 11 Jun 2025 | Scott William Morrison | Independent Director | Other Derivative Acquisition | +15,000 | $4.24 | 15,000 |
| 3 Jun 2025 | William Jones | Senior Vice President of Pharmaceutical Development | Derivative Exercise and Retained | +19,357 | $3.50 | 173,130 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 15 Sep 2026 | 17,180,341 | 20.4% | 18.2 |
| 31 Aug 2026 | 19,017,840 | 22.6% | 29.6 |
| 14 Aug 2026 | 19,127,098 | 22.7% | 22.5 |
| 31 Jul 2026 | 18,310,256 | 21.8% | 22.5 |
| 15 Jul 2026 | 18,061,919 | 21.5% | 12.6 |
| 30 Jun 2026 | 18,819,891 | 22.4% | 12.4 |
No comments yet — be the first to weigh in on CRVS.